HCMI: Human Cancer Models Initiative

The Human Cancer Models Initiative (HCMI) is an international consortium that is generating novel, next-generation, tumor-derived culture models annotated with genomic, clinical, and biospecimen data. HCMI-developed models and case-associated data are available as a community resource. NCI is contributing to the initiative by supporting four Cancer Model Development Centers (CMDCs).

Banner for Human Cancer Model Initiative

News & Publications

previousnext
February, 2021

The Human Cancer Models Initiative (HCMI) is an international collaboration between the National Cancer Institute (NCI), Cancer Research UK (CRUK), Wellcome Sanger Institute (WSI), and foundation Hubrecht Organoid Technology (HUB). The goal of...

August, 2020

Overview

The Human Cancer Models Initiative (HCMI) is an international consortium of the National Cancer Institute (NCI), Wellcome Sanger Institute, Cancer Research UK, and Hubrecht Organoid Technology. The goal of the consortium is to generate patient-derived...

December, 2019

NCI’s Human Cancer Models Initiative (HCMI)

The Human Cancer Models Initiative (HCMI) is an international consortium whose goal is to provide a community resource of ~1000 clinically and molecularly characterized next-generation (next-gen) cancer models. The next-gen...

August, 2019

As a contribution to efforts in precision oncology, the National Cancer Institute’s (NCI) Human Cancer Models Initiative (HCMI) is developing next-generation (next-gen)...

August, 2019

The use of cancer cell lines to model diverse cancer types have several challenges. Most of the commonly used cancer cell lines in research do not have clinical or therapeutic outcome data of the participant from which the cell line was derived. The genomic relatedness of the cell line to the...

O
O
O
O
O
Last updated: March 17, 2021